|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/05 | (2006.01) |
| A61K 31/08 | (2006.01) | ||
| A61K 31/192 | (2006.01) | ||
| A61K 31/352 | (2006.01) | ||
| A61K 31/485 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/555 | (2006.01) | ||
| A61K 31/7068 | (2006.01) |
| (11) | Number of the document | 3937914 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20712673.1 |
| Date of filing the European patent application | 2020-03-13 | |
| (97) | Date of publication of the European application | 2022-01-19 |
| (45) | Date of publication and mention of the grant of the patent | 2023-08-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/GB2020/050638 |
| Date | 2020-03-13 |
| (87) | Number | WO 2020/188255 |
| Date | 2020-09-24 |
| (30) | Number | Date | Country code |
| 201903546 | 2019-03-15 | GB |
| (72) |
LIU, Wai , GB
DALGLEISH, Angus , GB
|
| (73) |
LDN Pharma Limited ,
45 Gresham Street, London EC2V 7BG,
GB
|
| (54) | CANCER TREATMENT COMPRISING NALTREXONE AND A CANNABINOID |
| CANCER TREATMENT COMPRISING NALTREXONE AND A CANNABINOID |